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In the clinical context of antiviral drug resistance, treating
physicians need to adopt therapeutic strategies that
effectively control viral replication in the ﬁrst place, but
if treatment failure does occur, then a knowledge of cross-
resistance is needed in order to tailor appropriate “add-on”
therapy. Finally, the role of host genetics in inﬂuencing the
outcome of HBV disease in the context of natural history and
therapy is beginning to aid understanding in pathogenesis
and, when this knowledge is linked to pathogen-speciﬁc
databases, this should translate into more individualised
and effective patient care.
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Despite the availability of effective vaccines, chronic
hepatitis B (CHB) remains a signiﬁcant health burden
worldwide. In clinical ﬁelds, hepatitis B surface antigen
(HBsAg) has long served as a qualitative diagnostic marker
for HBV infection. HBsAg seroclearance is considered the
closest-to-cure outcome of hepatitis B virus infection,
reﬂecting immunological control of infection. Recently,
retrospective and prospective studies have shown that
HBsAg levels change along the natural history of CHB, and
that HBsAg levels in patients undergoing antiviral therapy
suggest a role for HBsAg quantitation in monitoring response
to therapy. There is increasing evidence that baseline
HBsAg levels and HBsAg kinetics during antiviral therapy
are predictive of treatment result. Notably, advances have
been made in the development of quantitative HBsAg assays,
which have allowed viral replication monitoring, and there
is an opportunity to make maximal use of quantitative HBsAg
to elucidate its role in clinical ﬁelds. Quantitative HBsAg
appear to be very promising as baseline and early on-
treatment predictors of sustained viral suppression and
HBsAg clearance. Further studies are required to validate
the use of these tools.
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In order to meet the global target of controlling tuberculosis
(TB), much emphasis has been placed on the development of
new tools for the purpose, to complement the enhancement
of existing programmatic activities in various countries
and geographical regions worldwide. The development of
new tools can be divided into 4 main areas. The ﬁrst
area is concerned with advances in the diagnosis of
TB and rapid assessment of drug susceptibility of the
Mycobacterium tuberculosis strains causing the disease.
The new tools developed ultilize the molecular approach or
phenotypic methods. A quite signiﬁcant recent development
has been that of a commercially available tool that rapidly
detects the presence of M. tuberculosis in the sputum
specimen, alongside performance of drug susceptibility
testing, especially to rifampicin. This apparently robust
test requires minimal manual skill, and appears readily
applicable at the point of care. However, it is clear
that the availability of new diagnostic tools does not
necessarily equate to their adoption, the translation of
policy into practice requires identiﬁcation of obstacles
and their resolution. Regarding the development of new
anti-tuberculosis drugs which constitutes the second area,
quite a number of new compounds are on the horizon.
Several are in Phase II and Phase III of clinical trials. Aside
from the rifamycins already in use, the diarylquinoline,
nitroimidazoles and the newer ﬂuoroquinolones appear to
hold the highest promise for clinical application in TB
treatment in the near future. Other potentially useful
compounds might include the ethylenediamines and the
oxazolidinones. Despite the encouraging progress, there
remains the important challenge of lack of global clinical
trial capacity to support the new drugs developed to gain
timely registration. The third area is clearly related to
TB vaccine development. The only TB vaccine available
for use today is bacillus Calmette Guerin which needs
improvement. There is an urgent need for developing a
modern, safe and effective TB vaccine to prevent all
forms of disease, in all age groups and among people
with HIV infection. Several vaccine candidates are now
in Phase II clinical development. The most promising ones
appear to be the recombinant forms of BCG, other live
mycobacterial vaccines and vaccines based on genetic
attenuation of M. tuberculosis. The last area is connected
with the development of biomarkers for monitoring disease
activity and predicting the outcome of TB treatment.
The advancement in this area has been relatively tardy.
Hopefully a combination of biomarkers might address the
issue better. It is clear that much more work is still required
here. Thus the past decade has witnessed a renaissance of
activities in the development of new tools for achieving
TB control globally. The fruitful outcome of these activities
have furnished high hopes for better control of TB, the
formidable foe of mankind, in the decade to come.
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Efforts to control the global TB epidemic have been
hampered by the lack of accurate and rapid diagnostic
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tools which may be applied at the point-of-care. TB control
programmes of disease-endemic countries still depend on
sputum smear microscopy which detects only ~50% of
culture positive pulmonary TB cases. Diagnosis of smear-
negative TB in paediatric and HIV populations, and of
extrapulmonary TB present a major challenge. The global
rise of MDR and XDRTB has added to the burden of TB
control programmes in developing countries which lack
laboratory capacity for drug susceptibility testing. Recent
years have seen rapid progress in the development of
new TB diagnostics. The task remains for these tools to
be made accessible to resource-constrained, tuberculosis-
endemic settings where they are most needed.
Light emitting diode (LED) microscopes have been shown to
be more sensitive than Ziehl-Neelsen (ZN) microscopy, with
operational and cost beneﬁts over conventional ﬂuorescent
microscopy and ZN microscopy.
The Xpert® MTB/RIF test (Cepheid, USA), an automated real-
time PCR assay which simultaneously detects Rifampicin
resistance, can be easily performed with little staff training.
It has been recently shown to have high diagnostic accuracy
in smear negative samples and HIV patients in close to point-
of- care settings. The GenoType® MDTBR (Hain LifeScience
GmbH, Germany), a molecular line probe assay based
on reverse hybridization technology, has demonstrated
accuracy for the rapid detection of MDRTB in smear positive
sputum specimens.
Liquid media-based methods for culture and drug
sensitivity testing are faster and more sensitive than
solid media, but require expensive and sophisticated
laboratory infrastructure. The Microscopically Observed
Drug Susceptibility (MODS) assay and thin layer agar (TLA)
assays are inexpensive and rapid tests which have shown
a high degree of accuracy for detection of rifampicin
and isoniazid resistance and have been proposed as an
interim solution in resource-limited settings until capacity
for genotypic or automated liquid culture drug susceptibility
testing is developed.
The interferon gamma release assays (IGRAs) have
demonstrated improved speciﬁcity and sensitivity over the
century old tuberculin skin test (TST) for detection of
latent TB infection. The IGRAs however do not distinguish
between latent and active TB and have a limited role in
diagnosing active TB in endemic settings. There is ongoing
research on the use of these tests on non-blood samples
from compartments of disease (eg bronchoalveolar lavage
ﬂuid) for diagnosis of active TB.
Urine is a convenient clinical specimen, and urinary
mycobacterial lipoarabinomannan (LAM) and trans-renal my-
cobacterial DNA appear promising as diagnostic tools in HIV-
infected individuals with advanced immunosuppression.
It is anticipated that the widespread implementation of
more accurate and rapid diagnostic tools will result in
increased TB case detection. This in turn must lead to
prompt and appropriate treatment of the TB case until
cure.
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Aims: The ﬁrst XDRTB emerged in 2005. Now it is
presented in at least 58 countries. Estimated fatality rate is
approximately 50%. China is one of the world’s 22 countries
with the highest burden of tuberculosis. China is also one of
the world’s 27 countries with the highest burden of MDR-TB/
XDR-TB. However, there is little information on the clinical
characteristics, management and treatment outcomes for
XDRTB patients in China. We try to address this issue by
collecting different reports from China so as to obtain a
whole picture about the features of XDRTB in China.
Methods: All pulmonary TB patients being reported were
diagnosed by sputum culture and their HIV status was
negative. XDR was conformed by DST which was done
on all culture-positive isolates by BACTEC 960 system.
Individualized treatment regimen was tailored by doctors
for these patients on the basis of DST results and history of
drugs taken by the patients. The recommended regimen
by WHO is the combination of at least four drugs to
which the Mycobacterium tuberculosis isolate is likely to
be susceptible. Drugs are chosen with a stepwise selection
process through ﬁve groups on the basis of efﬁcacy,
safety and cost. The clinical characteristics and treatment
outcome of XDRTB patients were compared with non-MDR
retreated patients and non-XDR MDR-TB patients.
Results: XDR PTB patients complained much more clinical
symptoms mainly including cough with sputum, weight loss,
sweating and short of breath as compared to retreated
non-MDR PTB patients. The extent of disease in XDRTB
and non-XDR MDR-TB was both large. At least 3 lung ﬁelds
were involved in 90.5% of XDR-TB patients and in 80.7%
of non-XDR MDR-TB (P= 0.008). 40.5% of XDR-TB patients
were complicated by diabetes, other chronic lung diseases,
liver disease, signiﬁcantly higher as compared with non-XDR
MDR-TB patients (P= 0.002). Micronodules, consolidations,
cavities were the most frequent CT abnormalities and
were seen in all XDR-TB patients (100%). Bronchiectasis,
tree-in-bud appearance, emphysema, pleural effusion,
lymphadenopathy, bronchopleural ﬁstula, empyema and
lobular consolidations were also found. Compared with non-
XDR MDR-TB, XDR-TB showed a signiﬁcantly larger extent of
cavities and consolidation (P< 0.05). With respect to other
CT features, there were no signiﬁcant differences between
them. In general, XDR-TB tends to have more extensive
consolidation and cavities. The resistance rates to other
drugs except for isoniazid and rifampicin were signiﬁcantly
higher in patients with XDR-TB. Average number of drugs to
which resistance was shown in XDR was 7, in non-XDR MDR
was 5.Treatment failure was more common in patients with
XDR-TB. Cure and treatment completion rate in XDR-TB was
only 14.89%, obviously lower than that in non-XDR MDR-TB,
whereas the mortality and treatment default did not differ
signiﬁcantly.
Conclusions: Tuberculosis treatment becomes challenging
following the emergence of MDR/XDRTB. XDR-TB has
signiﬁcantly worse short- and long-term outcomes because
of high resistant rate, extensive lung injury, lack of
potent bactericidal drugs, lengthy treatment duration and
toxicities of second-line medications.
